Ona Therapeutics SL is accelerating development of its first-in-class antibody-drug conjugate (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer ...

Tumor ablation, and ablative radiation therapies such as stereotactic body radiation therapy (SBRT), are mainstays of minimally invasive solid cancer ... cell death markers. However, despite ...

Some of these markers had a proven better sensitivity ... papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

In combination with established tumor markers, EDTA-plasma M2-PK is a useful ... melanoma and other solid tumors. Tumor M2-PK can be detected in EDTA-plasma and in the feces.

South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

For instance, understanding the differences between early and late-stage cancers, how pervasively specific cancers spread, ...

Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...

Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline ...